Published in Vaccine Weekly, July 13th, 2005
"We previously demonstrated that interleukin (IL)-4 gene-transfected glioma cell vaccines induce effective therapeutic immunity in preclinical glioma models, and have initiated phase I trials of these vaccines in patients with malignant gliomas. To gain additional mechanistic insight into the efficacy of this approach, we have treated mice bearing the MCA205 (H-2(b)) or CMS-4 (H-2(d)) sarcomas," investigators in the United States report.
"IL-12/23 p40-/- and IFN-gamma-/- mice, which were able to reject the initial inoculation of IL-4 expressing tumors, failed to mount a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.